Herpes zoster ophthalmicus

1. Recombinant zoster vaccine lowers the risk of herpes zoster ophthalmicus in humans.

   “The vaccine also substantially reduces the risk of herpes zoster ophthalmicus (HZO)”

   Reviewimmunocompetent

   Efficacy and Effectiveness of the Recombinant Zoster Vaccine Against Herpes Zoster, Herpes Zoster Ophthalmicus, Postherpetic Neuralgia and Dementia: A Systematic Review and Meta-Analysis

   Reviews in medical virology·1 Sep 2026

More on Recombinant zoster vaccine

1. Herpes zoster ophthalmicus raises the risk of dementia in humans (2.45% vs. 1.88%; aHR 1.37, 95% CI 1.24-1.48).

   “HZO was associated with higher 3-year incident dementia risk compared with uncomplicated nonophthalmic zoster (2.45% vs. 1.88%; aHR 1.37, 95% CI 1.24-1.48).”

   Humanscompared with uncomplicated nonophthalmic zoster3 years

   Herpes Zoster Ophthalmicus and 3-Year Dementia Risk: Association and Modification by Prior Zoster Vaccination in a Large US Cohort

   Cornea·18 Aug 2026

More on Dementia